SafeStitch Medical®, Inc. Will Attend the Abdominal Wall Reconstruction Conference to Present the AMID Hernia Fixation Device

Dr. Charles Filipi, Chief Medical Officer at SafeStitch Medical, Inc.
(Photo: Business Wire)

Dr. Charles Filipi, Chief Medical Officer at SafeStitch Medical, Inc. (Photo: Business Wire)

MIAMI--()--SafeStitch Medical®, Inc. (OTCBB:SFES), will attend the Abdominal Wall Reconstruction Conference (AWR) in Washington DC, June 14-16, 2012 to present the AMID™ Hernia Fixation Device (AMID HFD™).

“We are excited to be exhibiting at the AWR this year. The AMID Hernia Fixation Device is used for both inguinal and ventral hernia surgeries. We believe the ventral hernia repair market can benefit from the AMID HFD,” said Jeffrey Spragens, President and CEO of SafeStitch Medical.

For inguinal hernia repair using the Lichtenstein method, the innovative design of the AMID HFD fixates mesh by delivering staples in a parallel plane to the femoral vessels, which may help avoid vascular injury. The AMID HFD allows for mesh manipulation, mesh fixation and skin closure.

Ventral hernia repair can be complex and time consuming. The AMID HFD is easy to use, has a stapler counter and mesh manipulators that position the mesh before staple firing. We believe the AMID HFD avoids the need for suture placement and tying and may make large ventral hernia repair simpler,” said Dr. Charles Filipi, Chief Medical Officer of SafeStitch Medical.

The Abdominal Wall Reconstruction Conference is being held at the JW Marriot in Washington DC, June 14-16, 2012. Please visit booth #302 in the Capitol Ballroom to learn more about the AMID Hernia Fixation Device.

The AMID Hernia Fixation Device is sold nationwide.

About Dr. Charles Filipi

Dr. Charles Filipi is SafeStitch’s Chief Medical Officer and Professor of Surgery in the Department of Surgery at Creighton University School of Medicine in Omaha, Nebraska. He has published 101 peer reviewed articles and 50 book chapters. He has been the inventor on over 15 patents and five years ago became medical director of SafeStitch Medical, Inc. Dr. Filipi continues to see patients one day a week and devotes five days a week to research. His primary interests are intra-luminal surgery for the correction of gastroesophageal reflux disease and obesity, Barrett’s esophagus mucosal excision, stapled inguinal hernia repair and esophageal force feedback dilation.

About SafeStitch Medical, Inc.

Miami, Florida-based SafeStitch Medical, Inc. is a publicly traded medical device company founded by Charles J. Filipi M.D. and Jeffrey G. Spragens, in 2005, to develop a prototype for a minimally invasive obesity procedure. In the summer of 2006, Phillip Frost M.D., Chairman and CEO of OPKO Health, Inc. and Jane Hsiao Ph.D., Vice-Chairman and Chief Technical Officer of OPKO Health, Inc. became partners in SafeStitch Medical, Inc. and expanded SafeStitch’s mission to develop and market the best in class disposable medical devices to advance minimally invasive surgery for hernia repair, treatment of obesity and other gastroesophageal disorders. Information about the Company may be found on its website at: www.safestitch.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipate," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development and commercialization efforts, and our ability to significantly improve clinical outcomes in patients, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors, including those described herein and in our filings with the Securities and Exchange Commission, could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include: whether the ventral hernia market can benefit from the AMID HFD, whether the AMID HFD may help avoid vascular injury; whether the AMID HFD is easy to use; and whether it may make large ventral hernia repair simpler. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50305513&lang=en

Contacts

SafeStitch Medical, Inc.
Serina Lutz, 305-575-4609
serina@safestitch.com

Release Summary

SafeStitch Medical, Inc. is presenting the AMID Hernia Fixation Device at the Abdominal Wall Reconstruction Conference in Washington DC June 14 - 16.

Contacts

SafeStitch Medical, Inc.
Serina Lutz, 305-575-4609
serina@safestitch.com